Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation)

Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation)

The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials have demonstrated the clinical benefit as well as...

Full description

Bibliographic Details
Main Authors: L. Yu. Vladimirova, I. L. Popova, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, A. A. Lianova, A. E. Storozhakova, L. A. Ryadinskaya, S. N. Kabanov, E. A. Kalabanova
Format: Article
Language:Russian
Published: Remedium Group LLC 2022-06-01
Series:Медицинский совет
Subjects:
nivolumab
non-small cell lung cancer
brain metastases
abscopic effect
radiation therapy
immunotherapy
checkpoint inhibitors
Online Access:https://www.med-sovet.pro/jour/article/view/6932

Internet

https://www.med-sovet.pro/jour/article/view/6932

Similar Items